Erenumab

Aimovig Under Review for Migraine Prophylaxis

Aimovig Under Review for Migraine Prophylaxis

By

The FDA has accepted for review the Biologics License Application for Aimovig for migraine prophylaxis in patients experiencing more than 4 migraine days per month.

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

Anti-CGRP Receptor Antibody Erenumab Reduces Monthly Migraine Days

By

In a phase 3 trial, treatment with erenumab reduced migraine frequency, monthly migraine days, and migraine medication use in patients with episodic migraine.

Sign Up for Free e-Newsletters